Bronchogen

It's like a cough remedy whose label lists the ingredients in two different orders depending on which leaflet you read. The rat tests on it look encouraging, but nobody has tried it on people, and you can't be fully sure which version the tests were on.

Bronchogen is a short four-amino-acid peptide, usually Ala-Glu-Asp-Leu (AEDL). Per the Khavinson group, it acts through the generic short-peptide 'bioregulator' model: it enters cells and binds DNA (reported in the major groove at guanine) and histones, changing which genes are switched on in airway cells. In cultured human airway cells it is reported to raise markers of cell growth and of airway-cell maturity and mucus production, and in a rat COPD model it reduced inflammation and airway-lining damage. None of this has been confirmed in humans, and the direct gene-regulation model is not established outside the originating group.

Research contexts. Not proven uses, and not recommendations.

None found. We found no completed, registered or indexed human trial of Bronchogen for COPD, asthma, bronchitis or any other outcome, and no human safety or dosing data. The Khavinson group's 2020 COVID-19 review states that oral Bronchogen is effective for lung disease in patients, but the references we could check behind that statement were cell-culture studies. What exists is two rat studies of a lab-made COPD model, human embryonic airway cells in a dish, test-tube DNA chemistry and plant work. Any claim that it repairs or protects human lungs is unproven.

• !No human efficacy or safety data; the evidence is rat, cell-culture and test-tube work.
• !Claims of clinical effectiveness in the originating group's reviews are not backed by any human trial we could find.
• !Sequence confusion: the group's own papers give both Ala-Glu-Asp-Leu (AEDL) and Ala-Asp-Glu-Leu (ADEL), which are different molecules, so it is unclear which one the published results apply to or what a vial contains.
• !Heavy reliance on one research tradition with little independent replication.
• !Sold in the UK as an unlicensed grey-market 'research' peptide (typically a 20 mg freeze-dried vial labelled 'not for human or veterinary use'); no identity, purity, sterility or endotoxin guarantees.
• !Self-treating breathing problems with an unproven peptide could delay effective treatment for asthma, COPD or something more serious.
• !The proposed 'peptide binds DNA and directly regulates genes' mechanism is contested and not well established outside the originating group.

Bronchogen is not a licensed medicine in the UK and holds no MHRA marketing authorisation. It is not an approved or recognised treatment for any lung or airway condition, and we found no UK clinical trials of it. In practice it is sold online by UK 'research peptide' sites as a freeze-dried powder in vials, labelled for laboratory research only and 'not for human or veterinary use'. Selling or supplying it for human use would engage the Human Medicines Regulations 2012, and a UK clinician cannot prescribe it as a recognised therapy.

• · N/A· None found

  No human trials of Bronchogen identified

  PubMed and Europe PMC searches found no indexed human study of Bronchogen. Evidence is rat, cell-culture and test-tube data.

1. 01
   Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology — Kuzubova NA, Lebedeva ES, Dvorakovskaya IV, Surkova EA, Platonova IS, Titova ON, Bulletin of Experimental Biology and Medicine (2015)

   Rat COPD model (60 days of nitrogen dioxide); one month of Bronchogen reduced airway remodelling and inflammation and raised secretory IgA. Animal data, St Petersburg pulmonology institute.

2. 02
   [Antiinflammatory and regenerative effect of peptide therapy in the model of obstructive lung pathology] — Titova ON, Kuzubova NA, Lebedeva ES, Preobrazhenskaya TN, Surkova EA, Dvorakovskaya IV, Rossiiskii Fiziologicheskii Zhurnal imeni I.M. Sechenova (2017)

   Russian-language follow-up in the same rat COPD model: lower neutrophilic inflammation, restored airway lining, more secretory IgA and surfactant protein B. Animal data.

3. 03
   Peptide regulation of gene expression and protein synthesis in bronchial epithelium — Khavinson VKh, Tendler SM, Vanyushin BF, et al., Lung (2014)

   Human embryonic bronchial cell cultures plus DNA-binding chemistry. Note: this paper names the peptide Ala-Asp-Glu-Leu (ADEL), not AEDL. Lab data from the originating group.

4. 04
   Peptides tissue-specifically stimulate cell differentiation during their aging — Khavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM, Bulletin of Experimental Biology and Medicine (2012)

   Cell-culture study naming bronchogen as Ala-Glu-Asp-Leu; raised differentiation factors in ageing bronchial cell cultures. Lab data.

5. 05
   Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability — Monaselidze JR, Khavinson VKh, Gorgoshidze MZ, et al., Bulletin of Experimental Biology and Medicine (2011)

   Test-tube DNA-melting study. Cited mainly because its title gives the sequence as Ala-Asp-Glu-Leu, showing the inconsistency in the originating literature.

6. 06
   Peptide Regulation of Gene Expression: A Systematic Review — Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR, Molecules (2021)

   Originating group's review; table lists 'AEDL, Bronchogen'. Used for the name-to-sequence match.

7. 07
   Peptides: Prospects for Use in the Treatment of COVID-19 — Khavinson V, Linkova N, Dyatlova A, Kuznik B, Umnov R, Molecules (2020)

   Originating group's review asserting oral AEDL is effective in COPD and chronic bronchitis. Cited to show the claim; the supporting references we checked were cell-culture work, not human trials.